|
ID |
Project Title |
Collaboration Partners(Designated DevelopmentPartner is #1) |
Disease |
Intervention |
Stage |
Awarded Amount ?¥? |
AwardedAmount ($) |
Continuing |
|
G2017-203 |
Preclinicaldevelopment and phase I activities on aselectedaminopyrazolecompound for visceralleishmaniasis |
1. DNDi2. Takeda PharmaceuticalCompany Limited |
Leishmaniasis |
Drug |
PreclinicalDevelopment,Clinical PhI |
¥604,775,700 |
$5,636,307 |
G2014-208 |
|
G2017-211 |
Process Developmentand ClinicalManufacturing of anImmuno-focused,Mosquito-based Pan-malaria transmission-blocking vaccine:AnAPN1 v. 2.0. |
1. University of Florida2. CellFree Sciences Co. Ltd.3. Ology Bioservices Inc.4. Hamamatsu Pharma Research(HPR)5. Infectious Disease ResearchInstitute (IDRI)6. Centre Pasteur du Cameroon(CPC) |
Malaria |
Vaccine |
PreclinicalDevelopment |
¥348,421,798 |
$3,247,174 |
G2015-214 |
|
G2017-101 |
Lead optimization ofnovel azetidine-basedtryptophan synthaseinhibitors as newmechanism of actiontreatment oftuberculosis |
1. Broad Institute2. Eisai Co. Ltd.3. Colorado State University4. The University of Chicago5. TB Alliance |
Tuberculosis |
Drug |
LeadOptimization |
¥200,332,434 |
$1,867,031 |
New |
|
H2017-101 |
HTL for selectivePlasmodiumproteasome inhibitorsas new potentresistance-reversingantimalarials |
1. Medicines for MalariaVenture (MMV)2. The University of Melbourne'sBio21 Molecular Science andBiotechnology Institute3. Takeda Pharmaceutical Company Limited |
Malaria |
Drug |
Hit-to-Lead |
¥46,124,588 |
$429,866 |
T2015-134 |
|
H2017-102 |
New Hit-to-LeadActivity for New Anti-Malaria drugs betweenMMV and Sumitomo |
1. Medicines for MalariaVenture (MMV)2. Sumitomo Dainippon PharmaCo., Ltd. (Sumitomo) |
Malaria |
Drug |
Hit-to-Lead |
¥44,550,000 |
$415,191 |
S2014-211 |
|
H2017-103 |
Neglected TropicalDiseases DrugDiscovery Booster III |
1. DNDi – Drugs for NeglectedDiseases initiative2. Eisai Co. Ltd.3. Shionogi & Co., Ltd.4. Takeda PharmaceuticalCompany Ltd5. Astellas Pharma Inc. |
Chagas disease,VL |
Drug |
Hit-to-Lead |
¥149,832,868 |
$1,396,392 |
H2016-203 |
|
ID |
Project Title |
Collaboration Partners(Designated DevelopmentPartner is #1) |
Disease |
Intervention |
Stage |
Awarded Amount ?¥? |
AwardedAmount ($) |
Continuing |
|
S2017-221 |
Chagas disease andLeishmaniasisScreening betweenDNDi and DaiichiSankyo Novare |
1. DNDi2. Daiichi Sankyo RD Novare Co.,Ltd. |
Chagas disease,VL |
Drug |
Hit Identification |
¥11,900,000 |
$110,904 |
New |
|
T2017-272 |
Novel diagnostics forschistosomiasiscontrol: developmentof defined antigens fordetection ofSchistosoma infection-specific antibodies inblood and urine |
1. Lygature2. Institute of Tropical Medicine,Nagasaki University (NUITM)3. Department of Parasitology,Leiden University MedicalCenter (LUMC) |
Schistosomiasis |
Diagnostics |
ConceptDevelopment |
¥76,389,000 |
$711,920 |
New |
|
T2017-274 |
Identification ofVaccine Targets thatWill Block theInteraction ofPlasmodiumfalciparum MalariaParasites with aComplementRegulator |
1. The Pennsylvania State University2. Institute of Tropical Medicine,Nagasaki University3. Antigen Discovery, Inc. |
Malaria |
Vaccine |
AntigenIdentification |
¥88,190,035 |
$821,902 |
New |
|
T2017-278 |
Target determinationand exploratoryresearch for discoveryof new drugs againstChagas disease |
1. Nagasaki University(NEKKEN)2. National Institute of AdvancedIndustrial Science and Technology (AIST)3. High Energy AcceleratorResearch Organization (KEK)4. London School of Hygiene andTropical Medicine (LSHTM) |
Chagas Disease |
Drug |
TargetIdentification |
¥88,235,010 |
$822,321 |
New |
